公开(公告)号：US20140128475A1

公开(公告)日：2014-05-08

申请号：US14154688

申请日：2014-01-14

Applicant: ROHTO PHARMACEUTICAL CO., LTD.

Inventor： Takahiro KUROSE ,  Takayuki MIYANO ,  Mariyo KATO ,  Yoshihiro TAKAI

IPC: A61K31/121 ,  A61K45/06

CPC classification number: A61K31/121 ,  A61K9/0048 ,  A61K9/0053 ,  A61K45/06 ,  A61K47/02 ,  A61K47/26 ,  A61K47/44

Abstract: A prophylactic, ameliorating or therapeutic agent for a retinal disease, the agent comprising geranylgeranylacetone which(a) is a mixture of (5E,9E,13E)-geranylgeranylacetone and (5Z,9E,13E)-geranylgeranylacetone, the (5E,9E,13E)-geranylgeranylacetone content of the mixture being 80% by weight or more, (b) consists of (5E,9E,13E)-geranylgeranylacetone, or (c) consists of (5Z,9E,13E)-geranylgeranylacetone directly suppresses the death of a retinal cell, thereby fundamentally preventing, ameliorating or treating the retinal disease.

Abstract translation: （5E，9E，13E）ger anyl ger anyl anyl anyl one one and，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，， 13E）ger anyl ger anyl anyl anyl one one death death death death death death，，，，，death death death death death death death death death death death death death death death death death death death death death death death death death death death death death death death death death death death death death death death death death death death 的视网膜细胞，从而从根本上防止，改善或治疗视网膜疾病。

公开(公告)号：US20130303625A1

公开(公告)日：2013-11-14

申请号：US13775605

申请日：2013-02-25

Applicant: ROHTO PHARMACEUTICAL CO., LTD.

Inventor： Takahiro KUROSE ,  Takayuki MIYANO ,  Mariyo KATO ,  Yoshihiro TAKAI

IPC: A61K31/121

CPC classification number: A61K31/121 ,  A61K9/0048 ,  A61K9/0053 ,  A61K45/06 ,  A61K47/02 ,  A61K47/26 ,  A61K47/44

Abstract: A prophylactic, ameliorating or therapeutic agent for a retinal disease, the agent comprising geranylgeranylacetone which (a) is a mixture of (5E,9E,13E)-geranylgeranylacetone and (5Z,9E,13E)-geranylgeranylacetone, the (5E,9E,13E)-geranylgeranylacetone content of the mixture being 80% by weight or more, (b) consists of (5E,9E,13E)-geranylgeranylacetone, or (c) consists of (5Z,9E,13E)-geranylgeranylacetone directly suppresses the death of a retinal cell, thereby fundamentally preventing, ameliorating or treating the retinal disease.

Abstract translation: （5E，9E，13E）ger anyl ger anyl anyl anyl one one and，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，，， 13E）ger anyl ger anyl anyl anyl one one death death death death death death，，，，，death death death death death death death death death death death death death death death death death death death death death death death death death death death death death death death death death death death death death death death death death death death 的视网膜细胞，从而从根本上防止，改善或治疗视网膜疾病。

公开(公告)号：US20140350119A1

公开(公告)日：2014-11-27

申请号：US14460564

申请日：2014-08-15

Applicant: ROHTO PHARMACEUTICAL CO., LTD.

Inventor： Takayuki MIYANO ,  Takahiro KUROSE ,  Mariyo KATO ,  Yoshihiro TAKAI

IPC: A61K31/121

CPC classification number: A61K31/121 ,  A61K9/0048 ,  A61K47/02 ,  A61K47/26 ,  A61K47/44

Abstract: An ophthalmic composition comprising geranylgeranylacetone which (a) is a mixture of (5E,9E,13E)-geranylgeranylacetone and (5Z,9E,13E)-geranylgeranylacetone, the (5E,9E,13E)-geranylgeranylacetone content of the mixture being 80% by weight or more, (b) consists of (5E,9E,13E)-geranylgeranylacetone, or (c) consists of (5Z,9E,13E)-geranylgeranylacetone protects various types of retinal cells from degeneration, impairment or destruction, thereby remarkably promoting the survival. Consequently, the composition exhibits a remarkable effect of preventing, ameliorating or treating various retinal diseases. In addition, the composition hardly becomes white turbid during storage.

Abstract translation: （a）是（5E，9E，13E）ger anyl ger anyl anyl one one one and and ger ger ger ger ger ger ger ger ger ger ger An An An An An An An An ger ger％％％％％％％％％％％％％％％％％％％％％％％％％％ （5E，9E，13E） - ger ger ger ger anyl anyl anyl，，，，ger ably ably ably ably ably ably ably ably ably ably ably ably ably ably ably ably ably ably ably ably ably ably ably ably ably ably ably ably ably ably ably ably ably ably ably ably ably ably ably ably 促进生存。 因此，该组合物显示出预防，改善或治疗各种视网膜疾病的显着效果。 此外，组合物在储存期间几乎不变成白色混浊。

公开(公告)号：US20130303624A1

公开(公告)日：2013-11-14

申请号：US13775524

申请日：2013-02-25

Applicant: ROHTO PHARMACEUTICAL CO., LTD.

Inventor： Takayuki MIYANO ,  Takahiro KUROSE ,  Mariyo KATO ,  Yoshihiro TAKAI

IPC: A61K31/121 ,  A61K9/00

CPC classification number: A61K31/121 ,  A61K9/0048 ,  A61K47/02 ,  A61K47/26 ,  A61K47/44

Abstract: An ophthalmic composition comprising geranylgeranylacetone which (a) is a mixture of (5E,9E,13E)-geranylgeranylacetone and (5Z,9E,13E)-geranylgeranylacetone, the (5E,9E,13E)-geranylgeranylacetone content of the mixture being 80% by weight or more, (b) consists of (5E,9E,13E)-geranylgeranylacetone, or (c) consists of (5Z,9E,13E)-geranylgeranylacetone protects various types of retinal cells from degeneration, impairment or destruction, thereby remarkably promoting the survival. Consequently, the composition exhibits a remarkable effect of preventing, ameliorating or treating various retinal diseases. In addition, the composition hardly becomes white turbid during storage.

Abstract translation: （a）是（5E，9E，13E）ger anyl ger anyl anyl one one one and and ger ger ger ger ger ger ger ger ger ger ger An An An An An An An An ger ger％％％％％％％％％％％％％％％％％％％％％％％％％％ （5E，9E，13E） - ger ger ger ger anyl anyl anyl，，，，ger ably ably ably ably ably ably ably ably ably ably ably ably ably ably ably ably ably ably ably ably ably ably ably ably ably ably ably ably ably ably ably ably ably ably ably ably ably ably ably ably 促进生存。 因此，该组合物显示出预防，改善或治疗各种视网膜疾病的显着效果。 此外，组合物在储存期间几乎不变成白色混浊。